Lincoff 2023 — SELECT CVOT Semaglutide

New England Journal of Medicine·November 11, 2023

A. Michael Lincoff, Kirstine Brown-Frandsen, Helen M. Colhoun, John Deanfield, Scott S. Emerson, Sille Esbjerg, Søren Hardt-Lindberg, G. Kees Hovingh, Silvio E. Inzucchi, et al.

Summary

20% reduction in MACE (cardiovascular death, nonfatal MI, nonfatal stroke) in patients with obesity without diabetes. HR 0.80 (95% CI 0.72-0.90, p<0.001).

Study Details

Study Design

Phase 3 double-blind CVOT

Indication

CV outcomes in obesity without diabetes

Intervention

Semaglutide 2.4 mg weekly

Species

Human

Sample Size

17,604 subjects

Risk of Bias Assessment

Sponsor-funded